A review of scRNA-seq in lung cancer highlights how single-cell profiling can uncover clonal architecture, immune microenvironment remodeling, and mechanisms of resistance to targeted therapy and immune-checkpoint blockade, while a ClinicalTrials.gov survey identified ~380 ongoing or completed studies using scRNA-seq as a correlative or pharmacodynamic endpoint. The paper argues that pairing scRNA-seq with machine-learning methods can speed biomarker discovery, improve risk stratification, and support patient-specific therapeutic predictions.

Why It Matters To Your Practice

• scRNA-seq offers cell-level resolution that bulk assays miss, helping explain why patients with the same malignant neoplasm can respond differently to the same therapy.

• In lung cancer, it has exposed subclonal diversity and evolving tumor-immune interactions that can drive treatment failure.

• The growing use of scRNA-seq in trials suggests clinicians will increasingly encounter these data in translational reports and biomarker-driven studies.

Clinical Implications

• scRNA-seq may help identify resistant cell populations before radiographic progression is evident.

• It can refine selection of targeted agents or immunotherapy by revealing pathway activation, immune exclusion, or neoantigen-specific T-cell dynamics.

• For trial enrollment, scRNA-seq-based endpoints may become more relevant when assessing pharmacodynamic response or resistance mechanisms.

Insights

• The review summarizes the field from technical setup and platform evolution to computational pipelines needed for reliable interpretation.

• Machine-learning tools, including deep-learning classifiers and graph-based models, are being used to extract clinically useful patterns from high-dimensional single-cell data.

• Important barriers remain: cost, scalability, standardization, and the need for rigorous validation before routine clinical adoption.

The Bottom Line

• scRNA-seq is moving from a research tool toward a practical precision-oncology readout, especially in lung cancer.

• For clinicians, its near-term value is likely to be clearest in trials and referral-center workflows focused on resistance, biomarker discovery, and treatment personalization.